Treatment Guidelines for Antiviral Medications

Introduction to Treatment

• Treatment must begin within 5 days of symptom onset to ensure maximum effectiveness, as recommended by the World Health Organization 1
• COVID-19 treatment guidelines recommend vaccination as the primary preventive measure, with antiviral therapy such as Paxlovid as a treatment option for high-risk patients, as recommended by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) 2, 2, 1

Medication Administration and Recommendations

• The World Health Organization Guideline Development Group recommends nirmatrelvir/ritonavir (Paxlovid) and remdesivir as superior choices to molnupiravir due to greater reductions in hospitalization risk and fewer safety concerns 1
• Paxlovid is suggested as a treatment option for patients with non-severe COVID-19 at moderate risk of hospitalization, according to the British Medical Journal guidelines 1
• The standard dose of Paxlovid is 300 mg nirmatrelvir with 100 mg ritonavir, taken together twice daily for 5 days, with renal dose adjustments recommended for patients with moderate or severe impairment, as per treatment guidelines and the Leukemia journal 3, 4, 5, 6
• The following table outlines the dosing of Paxlovid based on renal function:

• Paxlovid has demonstrated an 86% reduction in hospitalization risk and 100% reduction in mortality compared to placebo in high-risk outpatients with mild-to-moderate COVID-19, as reported by the Infectious Diseases Society of America, the American College of Physicians, and supported by a meta-analysis (RR = 0.53 for hospitalization and RR = 0.36 for all-cause mortality) 7, 3, 5, 4, 1

Contraindications and Precautions

• The medication is contraindicated in pregnancy due to embryo-fetal toxicity in animal studies, and pregnancy testing should be performed before starting treatment, as advised by the World Health Organization 1
• The medication is not for use in children due to potential effects on bone formation, as recommended by the World Health Organization 1
• Reliable contraception should be used during treatment and for at least 4 days after the last dose for women of childbearing potential, and men planning to conceive should use reliable contraception during treatment and for at least 3 months afterward due to potential genotoxic effects on sperm, as advised by the World Health Organization 1
• Paxlovid is contraindicated in patients with a history of hypersensitivity to nirmatrelvir or ritonavir, significant drug-drug interactions, and co-administration with drugs highly dependent on CYP3A for clearance or potent CYP3A inducers, as recommended by the American College of Cardiology and the National Institutes of Health 1, 3
• Ritonavir is a strong CYP3A inhibitor that can significantly increase serum levels of many medications, and prior to prescribing, all patient medications should be reviewed to assess potential drug-drug interactions, as recommended by the American College of Physicians and the BMJ 5, 1

Alternative Treatments

• The American College of Physicians suggests considering molnupiravir as an alternative treatment when Paxlovid is contraindicated or unavailable, with a dosage as recommended, and must be initiated within 5 days of symptom onset, showing benefit in reducing mortality 5
• Remdesivir may be considered when Paxlovid is contraindicated due to drug interactions, requiring intravenous administration over 3 days, as recommended by the WHO Guideline Development Group 5, 1
• The American College of Physicians recommends against using ivermectin or sotrovimab for outpatient treatment of confirmed mild to moderate COVID-19, as they are ineffective treatments 5

Special Populations

• Paxlovid represents an option for pregnant people with COVID-19 to reduce disease progression risk, and breastfeeding is not contraindicated during Paxlovid treatment, as recommended by medical guidelines 8, 1
• High-risk patients who will benefit most from antiviral therapy include those with advanced age (especially ≥65 years), uncontrolled chronic medical conditions, immunocompromised status, unvaccinated status, and pregnancy, as recommended by the American College of Physicians, the Infectious Diseases Society of America, and the World Health Organization 3, 1, 5

Adverse Effects and Post-Treatment Care

• The most common adverse effects of Paxlovid are dysgeusia (taste disturbance) and diarrhea, as reported in the BMJ 1
• Patients who completed Paxlovid but still have persistent COVID-19 symptoms, antibiotics are not indicated unless there is clear evidence of a secondary bacterial infection, emphasizing the need for careful diagnosis 9
• The American College of Physicians does not recommend prophylactic antimicrobial therapy following COVID-19 treatment, and antibiotics should only be prescribed after Paxlovid treatment if there is clear clinical evidence of a bacterial infection requiring antibiotic therapy 9
• Avoid blind or inappropriate use of antibacterial drugs, especially broad-spectrum antibiotics, unless bacterial infection is suspected, as recommended by 10
• Dexamethasone is recommended for moderate COVID-19 (requiring O₂ support, saturation >90%) or severe COVID-19 (saturation <90-94%, respiratory rate >30/min) at a dose of 6 mg once daily for up to 10 days, according to the Leukemia journal 4